CD4^+^ and CD8^+^ T cells, the essential mediators of cellular immune responses, are produced in the thymus following sequential maturation stages. Hematopoietic progenitors first seed the thymus and then make T cell lineage specification and commitment decisions at the CD4^−^CD8^−^ double negative (DN) stage^[@R1],\ [@R2]^. While TCRβ recombination is completed at the CD25^+^CD44^−^ DN3 stage, rearrangements at the TCRα locus occur after DN cells mature to CD4^+^CD8^+^ double positive (DP) thymocytes, followed by negative and positive selection. The positively selected DP thymocytes first give rise to CD4^+^CD8^lo^ intermediate cells, which then differentiate into MHC class II-restricted CD4^+^ or MHC class I-restricted CD8^+^ single positive (SP) T cells, a decision known as CD4^+^ *versus* CD8^+^ lineage choice^[@R3]^.

The CD4^+^ *versus* CD8^+^ T cell lineage decision is influenced by the timing, intensity and duration of signals derived from TCR and cytokines^[@R3]^. A number of transcriptional factors intrinsically regulate this critical fate decision^[@R4],\ [@R5]^. Myb, GATA-3, Tox and Th-POK factors are specifically required for CD4^+^ T cell differentiation^[@R6],\ [@R7],\ [@R8],\ [@R9]^, and combined mutations of Runx1 and Runx3 completely abrogates CD8^+^ T cell production with limited effects on CD4^+^ T cell output^[@R10],\ [@R11]^. In terms of genetic interaction, Myb is required for induction of GATA-3 by TCR signals in DP thymocytes^[@R7]^. Upregulation of Th-POK is most evident in the CD4^+^8^lo^ intermediates^[@R12]^ and depends on both Tox and GATA-3^[@R6],\ [@R9]^. Th-POK is required to antagonize Runx3 activity and/or expression to promote CD4^+^ T cell lineage commitment^[@R11]^, and conversely, Runx3-mediated repression of Th-POK is critical for CD8^+^ T cell differentiation^[@R10],\ [@R12]^. Collectively, the Th-POK-Runx3 axis appears to be a critical convergence point in the CD4-CD8 lineage choice.

Once the decision to become either CD4^+^ or CD8^+^ SP thymocytes is made, lineage-inappropriate genes must be silenced in the committed T cells to ensure the distinct identity and functional divergence. Thus far, silencing of CD4^+^ T cell-specific genes, such as the CD4 coreceptor itself and the Th-POK transcription factor in CD8^+^ SP T cells is well characterized. *Cd4* repression is mediated by a \~430 bp silencer sequence in its first intron^[@R13]^. Th-POK is encoded by *Zbtb7b* (called *Thpok* here for simplicity and consistency with the literature), and its repression in CD8^+^ T cells is regulated by a \~560 bp sequence upstream of the *Thpok* exon 1a^[@R10],\ [@R12]^. Both *Cd4* and *Thpok* silencers contain consensus binding motifs for Runx factors, and combined mutations of Runx1 and Runx3 result in derepression of *Cd4* and *Thpok* in CD8^+^ T cells^[@R10],\ [@R13]^.

TCF-1 and LEF-1 are members of the TCF-LEF family of transcription factors and are abundantly expressed in T cells^[@R14],\ [@R15]^. TCF-1 is induced by Notch activation and is essential for specification of hematopoietic progenitors to T cell lineage^[@R16],\ [@R17]^. TCF-1 and LEF-1 then act together to promote complete T lineage commitment, β-selection and maturation of DN thymocytes to the DP stage^[@R18],\ [@R19]^. In these early thymocytes, TCF-1 also restrains the expression of LEF-1, Id2 and key components in the Notch signaling pathway to prevent malignant transformation^[@R18],\ [@R20],\ [@R21]^. However, because germline deletion of TCF-1 and LEF-1 causes severe early T cell developmental block and embryonic lethality, respectively^[@R19],\ [@R22]^, their roles beyond the DP stage are unknown. In this study, we overcame these obstacles by conditionally ablating both TCF-1 and LEF-1 in DP thymocytes using CD4-Cre. Loss of TCF-1 and LEF-1 specifically impaired the differentiation of CD4^+^ SP T cells from the bipotent DP and CD4^+^8^lo^ precursor cells and caused derepression of CD4 in committed CD8^+^ SP T cells. These findings broaden the spectra of TCF-1 and LEF-1-mediated regulatory activities in late stages of T cell development and reveal new insight into cell-fate decision mechanisms and establishment of cell identity.

Results {#S1}
=======

TCF-1 and LEF-1 are required for production of CD4^+^ T cells {#S2}
-------------------------------------------------------------

To investigate a role for TCF-1 and LEF-1 in late stages of T cell development, we used CD4-Cre to conditionally inactivate both factors in DP thymocytes. *Lef1*-floxed mice have been previously established^[@R18]^. The *Tcf7* gene (encoding TCF-1) was conditionally targeted by the International Knockout Mouse Consortium (IKMC, project 37596). Exon 4 of *Tcf7* was flanked by two LoxP sites, and deletion of this exon resulted in a nonsense frame-shift mutation ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Immunoblotting confirmed that CD4-Cre-mediated deletion was initiated in pre-select DP thymocytes and complete in the post-select DP cells, effectively eliminating all isoforms of both proteins ([Fig. 1a](#F1){ref-type="fig"}).

Due to the requirements of TCF-1 for T cell lineage specification, β-selection and thymocyte survival, germline deletion of TCF-1 results in diminished thymic cellularity to \<5% of wild-type mice^[@R22]^. In contrast, CD4-Cre-mediated late deletion of TCF-1 or both TCF-1 and LEF-1 (called *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ in this paper) only moderately reduced thymocyte counts, and CD4-Cre-*Lef1*^fl/fl^ (*Lef1*^−/−^) mice showed similar thymic cellularity as littermate controls ([Fig. 1b](#F1){ref-type="fig"}). Although the frequency of TCRβ^hi^ subset was not affected in *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ thymi, the expression of CD69 was reduced on *Tcf7*^−/−^*Lef1*^−/−^ TCRβ^hi^ thymocytes ([Fig. 1c](#F1){ref-type="fig"}). The decreased CD69 expression was unlikely to be a result of diminished TCR signaling, because TCR-dependent upregulation of *Gata3* and *Tox* was not affected in *Tcf7*^−/−^*Lef1*^−/−^ post-select DP thymocytes ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Downregulation of CD69 and CD24 marks intrathymic maturation of positively selected TCRβ^hi^ thymocytes. We found that maturation of CD24^+^CD69^+^ to CD24^−^CD69^−^ thymocytes was not detectably perturbed in *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ thymi ([Fig. 1d](#F1){ref-type="fig"}). The CD24^+^CD69^+^TCRβ^hi^ subset contains post-selected DP thymocytes and CD4^+^8^lo^ intermediates, which are immediate precursors to immature CD4^+^ or CD8^+^ SP thymocytes^[@R3]^. While T cell development was not apparently altered in *Lef1*^−/−^ mice, we observed the accumulation of cells with a DP phenotype and the concomitant reduction in both CD4^+^ and CD8^+^ SP thymocytes in *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ thymi ([Fig. 1e](#F1){ref-type="fig"}). The CD24^−^CD69^−^TCRβ^hi^ subset contains mature SP thymocytes only^[@R11]^, and deletion of TCF-1 alone or with LEF-1 progressively diminished the frequency of CD4^+^ SP T cells ([Fig. 1f](#F1){ref-type="fig"}), suggesting a requirement for TCF-1 and LEF-1 factors in effective production of CD4^+^ thymocytes.

TCF-1 and LEF-1 contribute to *Cd4* gene silencing in CD8^+^ T cells {#S3}
--------------------------------------------------------------------

A fraction of mature *Tcf7*^−/−^ CD8^+^ SP thymocytes showed increased expression of the CD4 coreceptor, and this fraction was substantially increased in *Tcf7*^−/−^*Lef1*^−/−^ CD8^+^ T cells ([Fig. 1f](#F1){ref-type="fig"}). By dividing the *Tcf7*^−/−^*Lef1*^−/−^ TCRβ^hi^ CD8^+^ cells into CD8^+^CD4^−^ and CD8^+^CD4^+^ subsets (the latter is called CD8\*4 hereafter to distinguish from true DP cells), we found that both subsets expressed CD8β protein ([Fig. 2a](#F2){ref-type="fig"}). Although not a focus of this study, we noted that both CD8α and CD8β expression was moderately reduced in *Tcf7*^−/−^*Lef1*^−/−^ TCRβ^hi^ CD8^+^ cells ([Fig. 2a](#F2){ref-type="fig"}). We next measured the expression of genes that are characteristic of CD4^+^ or CD8^+^ SP T cells. Runx3 is expressed in both cell types, but a distal promoter of the *Runx3* gene is exclusively utilized in CD8^+^ T cells, generating a *Runx3d* transcript^[@R23]^. On the other hand, *Thpok* is only expressed in CD4^+^ T cells. The CD4^−^CD8^+^ and CD8\*4 subsets from *Tcf7*^−/−^*Lef1*^−/−^ thymi both expressed *Runx3d* but not *Thpok* ([Fig. 2b](#F2){ref-type="fig"}). In addition, total *Runx3* and *Prf1* (encoding perforin) were more highly expressed in naïve CD8^+^ than in CD4^+^ SP T cells, and this trend was preserved in CD8^+^CD4^−^ and CD8\*4 subsets in *Tcf7*^−/−^*Lef1*^−/−^ animals ([Fig. 2b](#F2){ref-type="fig"}). These data suggest that the CD8\*4 cells from *Tcf7*^−/−^*Lef1*^−/−^ mice are *bona-fide* cytotoxic CD8^+^ T cells with derepressed CD4 coreceptor, similar to Runx3- or Runx3d-deficient CD8^+^ T cells^[@R11],\ [@R13]^.

To further substantiate this point, we crossed *Tcf7*^−/−^*Lef1*^−/−^ and control mice to an *H2-Ab1*^−/−^ background, in which CD4^+^ T cells were greatly diminished due to lack of MHC-II I-A and I-E molecules^[@R24]^. The MHC-I-selected T cells showed CD4 derepression in the absence of TCF-1 and LEF-1 ([Fig. 2c](#F2){ref-type="fig"}), formally excluding the possibility that the CD8\*4 T cells were CD4^+^ T cells with improper expression of CD8 coreceptors. These findings suggest a role of TCF-1 and LEF-1 in *Cd4* gene silencing in CD8^+^ T cells.

TCF-1 and LEF-1 are critical for CD4^+^ T cell fate decision {#S4}
------------------------------------------------------------

Due to CD4 derepression in *Tcf7*^−/−^*Lef1*^−/−^ CD8^+^ SP thymocytes, the true DP and the CD8\*4 cells cannot be phenotypically distinguished in the immature CD24^+^CD69^+^ TCRβ^hi^ compartment. To accurately measure CD4^+^ and CD8^+^ SP T cell output, we therefore focused on the mature CD24^−^CD69^−^ TCRβ^hi^ thymocytes, which do not contain DP cells in wild-type mice. Loss of TCF-1 alone caused a 40% reduction in mature CD4^+^ SP thymocytes, and deleting both TCF-1 and LEF-1 caused \>80% reduction ([Fig. 3a](#F3){ref-type="fig"}). Whereas TCF-1 deficiency did not have a significant impact on mature CD8^+^ SP thymocytes (counted as sum of CD8^+^CD4^−^ and CD8\*4 cells), loss of both factors substantially increased CD8^+^ SP T cell numbers ([Fig. 3a](#F3){ref-type="fig"}). The ratio of mature CD4^+^ to CD8^+^ SP cells is approximately 2:1 in wild-type mice, but this ratio was reduced to 1:1 in *Tcf7*^−/−^ mice and reversed to about 0.1:1 in *Tcf7*^−/−^*Lef1*^−/−^ animals ([Fig. 3b](#F3){ref-type="fig"}). The same phenotypic defects, including reduction in CD4^+^ SP T cell frequency and numbers and decreased CD4/CD8 ratio, persisted in the periphery ([Supplementary Fig. 3a-c](#SD1){ref-type="supplementary-material"}).

Germline deletion of TCF-1 reduces thymic cellularity by \>95%, partly due to a critical requirement of TCF-1 for survival of early thymocytes^[@R25]^. By measuring active caspase-3 and caspase-7, we confirmed that early deletion of TCF-1 caused caspase activation in \~35% of post-select TCRβ^hi^ thymocytes ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). However, the increase in caspase activation in TCRβ^hi^ thymocytes from *Tcf7*^−/−^ or *Tcf7*^−/−^ *Lef1*^−/−^ mice was rather moderate ([Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}), indicating that CD4-Cre-mediated late deletion of TCF-1 and LEF-1 greatly alleviated the dependence of post-select thymocytes on TCF-1 and LEF-1 for survival. Importantly, caspase activation was similar between mature CD4^+^ and CD8^+^ SP thymocytes in *Tcf7*^−/−^ or *Tcf7*^−/−^*Lef1*^−/−^ animals ([Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"}). These data suggest that TCF-1 and LEF-1 critically regulate CD4^+^ T cell fate decision, rather than preferentially promoting survival of CD4^+^ T cells. In addition, the residual CD4^+^ T cells in *H2-Ab1*^−/−^ mice, which may have been selected on the H-2O MHC-II molecule^[@R26]^, were completely abrogated by loss of TCF-1 and LEF-1 ([Fig. 2c](#F2){ref-type="fig"}), lending additional support for an essential role of TCF-1 and LEF-1 in promoting CD4^+^ lineage differentiation.

Deficiency in Th-POK or GATA-3 results in redirection of CD4^+^ T cells to the CD8^+^ lineage^[@R6],\ [@R8]^. In *Tcf7*^−/−^*Lef1*^−/−^ mice, the reduction of CD4^+^ SP thymocytes was accompanied by an increase in CD8^+^ SP cells ([Fig. 3a](#F3){ref-type="fig"}), indicative of lineage redirection. To further test this notion, we transplanted CD45.2^+^ bone marrow (BM) cells from *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ mice into irradiated congenic CD45.1^+^β2m^−/−^ recipients (*Lef1*^−/−^ cells were not tested because loss of LEF-1 alone showed little impact). The β2m^−/−^ mice are defective in MHC-I expression and thus have very few CD8^+^ SP T cells^[@R27]^. In β2m^−/−^ hosts, mature TCRβ^hi^ thymocytes derived from BM cells of littermate controls were predominantly CD4^+^ ([Fig. 3c,d](#F3){ref-type="fig"}). In contrast, *Tcf7*^−/−^ BM cells gave rise to substantial amounts of mature CD8^+^ thymocytes, and mature thymocytes generated from *Tcf7*^−/−^*Lef1*^−/−^ BM cells were predominantly CD8^+^ ([Fig. 3c,d](#F3){ref-type="fig"}). These data indicate that MHC-II-selected thymocytes undergo a fate change from CD4^+^ to CD8^+^ T cells in the absence of TCF-1 or both TCF-1 and LEF-1. Consistent with the essential role of TCF-1 and LEF-1 in *Cd4* silencing in CD8^+^ T cells ([Fig. 2](#F2){ref-type="fig"}), the redirected CD8^+^ T cells lacking TCF-1 or both factors continued to exhibit derepression of the CD4 coreceptor ([Fig. 3c](#F3){ref-type="fig"}).

In *Tcf7^−/−^*- or *Tcf7^−/−^Lef1^−/−^*-reconstituted β2m^−/−^ BM chimeras, the redirected CD8^+^ T cells persisted in the periphery ([Supplementary Fig. 4a,b](#SD1){ref-type="supplementary-material"}). To determine if the redirected cells truly acquired CD8^+^ T cell identity and function or were CD4^+^ T cells with aberrant CD8 expression, we sorted the redirected CD8^+^ cells from the *Tcf7^−/−^Lef1^−/−^* BM chimeras into two subsets, CD8^+^CD4^−^ and CD8\*4. Gene expression analysis revealed that both subsets expressed CD8^+^ T cell-specific *Runx3d* and higher basal amounts of *Prf1*, but express little, if any, CD4^+^ T cell-specific *Thpok* transcripts ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). We also activated the redirected CD8^+^ T cells *in vitro*. Similar to wild-type CD8^+^ T cells, the redirected *Tcf7^−/−^Lef1^−/−^* CD8^+^ T cells more proficiently produced granzyme B and interferon-γ, but less effectively produced IL-2 or induced CD40L than CD4^+^ T cells ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). These observations further corroborate a complete fate change of MHC-II-selected T cells to cytotoxic CD8^+^ T cell lineage in the absence of TCF-1 and LEF-1.

We next investigated if deficiency in TCF-1 and LEF-1 changed the fate of T cells that express a fixed MHC-II-restricted TCR. To this end, we crossed the OT-II CD4^+^ TCR transgene (TG) with *Tcf7*^−/−^*Lef1*^−/−^ mice. We detected the OT-II TCR by gating on TCRβ^hi^Vα2^+^ thymocytes, which are predominantly CD4^+^ T cells under TCF-1 and LEF-1-sufficient conditions ([Fig. 3e,f](#F3){ref-type="fig"}). In contrast, deletion of TCF-1 or both TCF-1 and LEF-1 reduced the frequency of TCRβ^hi^Vα2^+^ mature CD4^+^ thymocytes with a concomitant increase in the CD8^+^ compartment ([Fig. 3e,f](#F3){ref-type="fig"}). In these mice, derepression of CD4 was also observed in the redirected OT-II CD8^+^ T cells ([Fig. 3e](#F3){ref-type="fig"}). Of note, in the presence of the OT-II transgene, CD4-Cre-mediated deletion of TCF-1 or both factors caused more severe reduction in total thymic cellularity ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}, compare with [Fig. 1b](#F1){ref-type="fig"}). This is likely due to altered timing of target excision by CD4-Cre due to the TCR TG, because we observed early deletion of *Tcf7* and *Lef1* in DN thymocytes from OT-II TG *Tcf7*^−/−^*Lef1*^−/−^ mice ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). Nonetheless, mature OT-II^+^CD8^+^ thymocytes were more dominant over CD4^+^ SP thymocytes upon deletion of TCF-1 or both TCF-1 and LEF-1 ([Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}). Collectively, loss of TCF-1 and LEF-1 resulted in a fate change of MHC-II-selected cells to the CD8^+^ lineage, regardless if polyclonal TCRs or a fixed MHC-II-restricted TCR was expressed on the post-select DP thymocytes. These findings unambiguously reveal an essential role of TCF-1 and LEF-1 in directing the bipotent precursors to the CD4^+^ T cell lineage.

TCF-1 regulates balanced expression of *Thpok* and *Runx3d* {#S5}
-----------------------------------------------------------

Several transcriptional factors have been characterized as intrinsic regulators of CD4-CD8 fate decision. Among these, Myb, GATA-3, Tox and Th-POK factors direct post-select DP cells to the CD4^+^ T cell lineage, and Runx factors ensure CD8^+^ T cell differentiation^[@R4],\ [@R5]^. We thus investigated if TCF-1 and LEF-1 regulate these key factors involved in lineage choice. Because double deficiency in TCF-1 and LEF-1 resulted in strong CD4 derepression in CD8^+^ SP T cells ([Fig. 2](#F2){ref-type="fig"}), the resulting CD8\*4 cells cannot be adequately separated from actual post-select DP thymocytes in *Tcf7*^−/−^*Lef1*^−/−^ mice. To avoid misinterpretation of the data, we focused our gene expression analysis on *Tcf7*^−/−^ thymocytes.

To discern kinetic changes of gene expression at distinct stages prior to complete lineage commitment, we purified pre-select DP (TCRβ^lo-med^ DP), post-select DP (TCRβ^hi^ DP) and CD4^+^8^lo^ intermediates by cell sorting. Similar to immunoblotting results ([Fig. 1a](#F1){ref-type="fig"}), CD4-Cre-mediated deletion of *Tcf7* was more complete in post-select DP stage and beyond ([Fig. 4a](#F4){ref-type="fig"}). While *Tcf7* expression was relatively constant throughout these stages, *Lef1* exhibited dynamic changes similar to *Gata3* and *Tox*, as it was upregulated by positive selection signals and had a sustained high expression in CD4^+^8^lo^ thymocytes ([Fig. 4b,d,e](#F4){ref-type="fig"})^[@R6],\ [@R9]^. The induction of *Thpok* was more potent at the CD4^+^8^lo^ stage ([Fig. 4f](#F4){ref-type="fig"})^[@R12]^; in contrast, *Myb* expression was progressively downregulated in post-select DP and CD4^+^8^lo^ cells ([Fig. 4c](#F4){ref-type="fig"}). Deletion of TCF-1 did not affect the kinetic changes in *Gata3, Tox* and *Myb* expression ([Fig. 4c-e](#F4){ref-type="fig"}); but substantially diminished the expression of *Thpok* in both post-select DP and CD4^+^8^lo^ thymocytes ([Fig. 4f](#F4){ref-type="fig"}). TCF-1 deficiency did not significantly alter the expression of *Runx1* or total *Runx3* (transcribed from both distal and proximal promoters) ([Fig. 4g,h](#F4){ref-type="fig"}). Runx3 protein in CD8^+^ SP T cells is exclusively produced from the *Runx3d* transcript, and in fact, transcription from the *Runx3* distal promoter is initiated at the post-select DP stage^[@R11]^. Significantly, specific deletion of Runx3d and complete ablation of Runx3 show remarkably similar effects on CD8^+^ lineage differentiation and *Cd4* silencing in CD8^+^ T cells^[@R11],\ [@R23]^. Thus, *Runx3d* expression is more directly linked to the activity of Runx3 in lineage choice. Detection of *Runx3d* transcripts, using primers that were specifically complementary to cDNA transcribed from the distal promoter in quantitative RT-PCR, revealed that TCF-1 deficiency resulted in increased expression of *Runx3d* in both post-select DP and CD4^+^8^lo^ cells ([Fig. 4i](#F4){ref-type="fig"}). These gene expression analyses collectively suggest that TCF-1 and LEF-1 impinge on balanced expression of *Thpok* and *Runx3d* to regulate CD4-CD8 fate decision.

TCF-1 and LEF-1 act upstream of Th-POK to promote CD4^+^ T cell differentiation {#S6}
-------------------------------------------------------------------------------

Because Th-POK and Runx3d mutually antagonize each other's expression and/or activity^[@R11],\ [@R28]^, we next investigated which is the primary factor that acts downstream of TCF-1 and LEF-1. We crossed *Tcf7*^−/−^ or *Tcf7*^−/−^*Lef1*^−/−^ mice with a Th-POK TG driven by the human CD2 promoter. Consistent with previous reports^[@R6],\ [@R29]^, ectopic expression of Th-POK directed all post-select DP thymocytes to the CD4^+^ lineage, regardless of MHC restrictions. In Th-POK TG *Tcf7*^−/−^ mice, Th-POK overexpression suppressed CD8^+^ T cell differentiation and increased the frequency of CD4^+^ T cells in immature and mature TCRβ^hi^ thymocytes ([Fig. 5a](#F5){ref-type="fig"}). Importantly, Th-POK TG *Tcf7*^−/−^ mice had similar numbers of mature CD4^+^ SP thymocytes as littermate controls without the TG ([Fig. 5b](#F5){ref-type="fig"}), suggesting that ectopic Th-POK expression is sufficient to rescue CD4^+^ T cell differentiation defects caused by loss of TCF-1.

Although *Tcf7*^−/−^*Lef1*^−/−^ mice had increased CD8^+^ output at the expense of CD4^+^ T cells, ectopic Th-POK expression repressed CD8^+^ T cell differentiation in Th-POK TG *Tcf7*^−/−^*Lef1*^−/−^ mice ([Fig. 5a,b](#F5){ref-type="fig"}). Consequently, mature TCRβ^hi^ thymocytes in Th-POK TG *Tcf7*^−/−^*Lef1*^−/−^ mice were almost exclusively CD4^+^, and the frequency of CD4^+^ SP thymocytes in the immature TCRβ^hi^ subset was increased compared with *Tcf7*^−/−^*Lef1*^−/−^ mice (compare [Fig. 5a](#F5){ref-type="fig"} with [Fig. 1e,f](#F1){ref-type="fig"}). In Th-POK TG *Tcf7*^−/−^*Lef1*^−/−^ mice, the number of mature CD4^+^ SP thymocytes increased by about 50% over that in *Tcf7*^−/−^*Lef1*^−/−^ animals, but remained substantially lower than those in littermate controls without the TG ([Fig. 5b](#F5){ref-type="fig"}). These observations suggest that compared with loss of TCF-1 alone, double deficiency in TCF-1 and LEF-1 caused additional alterations, and as a result, the defective CD4^+^ T cell differentiation cannot be sufficiently reversed by overexpressing Th-POK. In line with this notion, the combination of Th-POK overexpression and TCF-1 and LEF-1 double deficiency may have more complex effects on late T cell development, causing further reduction in total thymocytes ([Fig. 5b](#F5){ref-type="fig"}) and less aggregated expression of the CD4 coreceptor in the "rectified" mature CD4^+^ SP thymocytes ([Fig. 5a](#F5){ref-type="fig"}).

We next examined the effect of ectopic Th-POK expression on CD4^+^ to CD8^+^ lineage redirection caused by loss of TCF-1 or both TCF-1 and LEF-1. We transplanted BM cells from Th-POK TG *Tcf7*^−/−^ or Th-POK TG *Tcf7*^−/−^*Lef1*^−/−^ mice into CD45.1^+^ β2m^−/−^ mice. In the chimeric hosts, lineage redirection was completely blocked by the Th-POK TG in mature TCRβ^hi^ thymocytes (compare [Fig. 5c](#F5){ref-type="fig"} with [3c](#F3){ref-type="fig"}). In line with this observation, ectopic Th-POK expression diminished *Runx3* and *Runx3d* in TCF-1-sufficient post-select DP and CD4^+^8^lo^ thymocytes, and more importantly, prevented *Runx3d* upregulation in *Tcf7*^−/−^ cells (compare [Fig. 5d](#F5){ref-type="fig"} with [4i](#F4){ref-type="fig"}). These data collectively suggest that Th-POK acts downstream of TCF-1 and LEF-1 in regulating the CD4-CD8 lineage choice.

We then investigated if TCF-1 directly regulates *Thpok* gene expression. Previous studies have demonstrated that the −17 kb to +1 kb region flanking the first *Thpok* coding exon contains all the *cis*-elements required for its dynamic expression during thymocyte development^[@R12]^. Within this region, we found seven conserved TCF-LEF consensus binding sequences (T/A)CAAAG, designated as A-G, between exons 1a and 2 of the *Thpok* gene ([Fig. 6a](#F6){ref-type="fig"}). We performed chromatin immunoprecipitation (ChIP) with a TCF-1 antibody^[@R30]^ or control IgG using sorted post-select DP and CD4^+^8^lo^ thymocytes. We observed enriched binding of TCF-1 to the *Lef1* and *Axin2* gene segments ([Fig. 6b](#F6){ref-type="fig"}), two known TCF-1 target genes. Among the seven conserved TCF-LEF motifs, TCF-1 bound specifically to motif D ([Fig. 6b](#F6){ref-type="fig"}). TCF-1 binding to these genomic locations was abrogated in sorted post-select DP and CD4^+^8^lo^ thymocytes from *Tcf7*^−/−^ mice ([Fig. 6b](#F6){ref-type="fig"}), indicating the binding specificity. It is important to note that motif D is located in a previously defined "general T lymphoid element" (GTE) which contributes to positive regulation of *Thpok* in T cells^[@R12]^. Analysis of data from a recent study that performed TCF-1 ChIP-Seq on whole thymocytes^[@R31]^ identified a strong TCF-1 binding peak at the *Thpok* GTE element ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}), consistent with our finding using the ChIP-PCR tiling assay.

The 473-bp GTE contains two sets of highly conserved CAAAG motifs ([Supplementary Fig. 7a,b](#SD1){ref-type="supplementary-material"}). To investigate the contribution of these potential TCF-1 sites to the enhancer activity of GTE, we cloned wild-type GTE either upstream or downstream of a luciferase reporter driven by an SV40 promoter. We then mutated both "CAAAG" motifs in the GTE to "accct" to generate mutant reporter constructs. Regardless of the location of insertion, inclusion of the wild-type GTE increased the reporter activity, and importantly, mutation of both TCF-1 sites almost completely abrogated the increase ([Fig. 6c](#F6){ref-type="fig"}). This was observed in EL-4 thymoma as well as 293T cell lines ([Supplementary Fig. 7c](#SD1){ref-type="supplementary-material"}). Collectively, these findings support the notion that TCF-1 acts directly upstream of Th-POK in directing the bipotent DP or CD4^+^8^lo^ precursors to the CD4^+^ T cell lineage.

TCF-1 and LEF-1 do not depend on Runx3 in T cell lineage choice {#S7}
---------------------------------------------------------------

We showed above that TCF-1 positively regulated *Thpok*, which in turn repressed *Runx3d* expression. A parallel mechanism could be that TCF-1 directly represses *Runx3d,* which then negatively regulates *Thpok*. To test this, we ablated total Runx3 expression by crossing CD4-Cre-*Runx3*^fl/fl^ (*Runx3*^−/−^) mice to *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ strains. *Runx3*^−/−^ mice have a moderate reduction of CD8^+^ SP T cells in the thymi and periphery^[@R23]^. However, *Tcf7*^−/−^*Runx3*^−/−^ mice showed clearly reduced CD4^+^ T cell frequency and numbers in both immature and mature TCRβ^hi^ thymocytes compared with *Runx3*^−/−^ mice ([Fig. 7a,b](#F7){ref-type="fig"}). Moreover, *Tcf7*^−/−^*Lef1*^−/−^*Runx3*^−/−^ mice exhibited more severe loss of mature CD4^+^ SP thymocytes, with CD8^+^ T cells remaining dominantly abundant, similar to *Tcf7*^−/−^*Lef1*^−/−^ animals (compare [Fig. 7a,b](#F7){ref-type="fig"} with [Fig. 1e,f](#F1){ref-type="fig"} and [3a](#F3){ref-type="fig"}). Thus, Runx3 deficiency failed to rectify defective CD4^+^ lineage choice in *Tcf7*^−/−^ or *Tcf7*^−/−^*Lef1*^−/−^ mice. In line with this, we found that *Thpok* expression in post-select DP and CD4^+^8^lo^ thymocytes from *Runx3*^−/−^ mice was similar to littermate controls, and importantly, *Tcf7*^−/−^*Runx3*^−/−^ post-select DP and CD4^+^8^lo^ thymocytes expressed similar lower amounts of *Thpok* transcripts as *Tcf7*^−/−^ cells ([Fig. 7c](#F7){ref-type="fig"}).

Overexpression of Runx3 increases CD8^+^ T cell output, but whether this is a result of lineage redirection remains controversial^[@R32]^. To determine if increased CD8^+^ T cell frequency and numbers in *Tcf7*^−/−^*Lef1*^−/−^ mice results from aberrant upregulation of Runx3d and ensuing lineage redirection, we made β2m^−/−^ BM chimeras with donor cells from *Runx3*^−/−^*, Tcf7*^−/−^*Runx3*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^*Runx3*^−/−^ mice. As expected, mature TCRβ^hi^ thymocytes derived from *Runx3*^−/−^ BM cells were predominantly CD4^+^ in the β2m^−/−^ recipients. However, mature TCRβ^hi^ thymocytes derived from *Tcf7*^−/−^*Runx3*^−/−^ or *Tcf7*^−/−^ *Lef1*^−/−^*Runx3*^−/−^ BM cells exhibited CD4^+^ to CD8^+^ T cell lineage redirection, similar to those from *Tcf7*^−/−^ or *Tcf7*^−/−^*Lef1*^−/−^ BM cells (compare [Fig. 7d](#F7){ref-type="fig"} with [Fig. 3c](#F3){ref-type="fig"}). Therefore, regardless if TCF-1 and LEF-1 directly or indirectly suppress *Runx3d* expression, Runx3 proteins are not essential for TCF-1- and LEF-1-mediated regulation of CD4-CD8 lineage choice.

TCF-1 and LEF-1 cooperate with Runx3 in *Cd4* gene silencing in CD8^+^ T cells {#S8}
------------------------------------------------------------------------------

Detailed mapping of *cis*-elements in the *Cd4* silencer has revealed that several sites, in addition to the Runx-binding motifs, contribute to stable repression of CD4 coreceptor in CD8^+^ T cells^[@R13],\ [@R33]^. However, the identity of the factors binding to these additional sites remains unknown. To better understand the role of TCF-1 and LEF-1 in this process, we performed ChIP-seq with anti-TCF-1^[@R30]^ or control IgG in naïve splenic CD8^+^ T cells and used the model-based analysis for ChIP-Seq (MACS) algorithm^[@R34]^ to identify TCF-1 binding peaks. By stringent criteria of ≥ 4 fold enrichment, p \< 10^−5^ and a false discovery rate (FDR) \< 5%, we identified 2,827 high-confidence, strong TCF-1 binding peaks. Using more permissive criteria of p \< 10^−3^, we located additional 6,577 weak TCF-1 peaks ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}). Genomic distribution analysis of all TCF-1 peaks revealed that only 6% were located in the promoter regions (−5k \~ +1 kb of transcription start sites) of known RefSeq genes ([Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}). Two histone modification marks, the activating H3K4me3 and repressive H3K27me3, were previously mapped by ChIP-seq in human naïve CD8^+^ T cells^[@R35]^. Peak overlap analysis showed that 15% of TCF-1 peaks in the promoter regions overlapped with H3K4me3, whereas the overlap with H3K27me3 was lower ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}). Among the strong TCF-1 binding peaks, we confirmed the direct association of TCF-1 with its known target genes including *Axin2* and *Lef1* ([Fig. 8a](#F8){ref-type="fig"} and data not shown). One TCF-1 binding peak was found in the first intron of *Cd4* at a location corresponding to the *Cd4* silencer ([Fig. 8a](#F8){ref-type="fig"}). Analysis of TCF-1 ChIP-Seq in whole thymocytes confirmed TCF-1 binding to the same location in the *Cd4* gene ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). In addition, a recent study reported Runx3 ChIP-Seq in CD8^+^ T cells and NK cells^[@R36]^. Collective analysis of these three sets of ChIP-seq data revealed that TCF-1 binding at the *Cd4* intron 1 was perfectly aligned with the Runx3 binding peak ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}), suggesting co-occupancy of TCF-1 and Runx factors at the *Cd4* silencer in CD8^+^ T cells. The \~430 bp *Cd4* silencer indeed contains a perfect TCF-LEF motif "ACAAAG" in its 3′-terminus, with two known Runx motifs in its 5′ half. We validated enriched TCF-1 occupancy at the *Cd4* silencer in wild-type CD8^+^ T cells, which was abrogated in *Tcf7*^−/−^ CD8^+^ T cells ([Fig. 8b](#F8){ref-type="fig"}). The *Cd4* silencer was not occupied by TCF-1 in CD4^+^ T cells ([Fig. 8b](#F8){ref-type="fig"}), suggesting lineage specificity. Consistent with this observation, Runx3 binding to the *Cd4* silencer is specific to CD8^+^ T cells and not observed in NK cells^[@R36]^.

*De novo* motif discovery analysis of the strong TCF-1 binding peaks recovered the known consensus TCF-LEF motif in 52.5% and the Runx motif in 54.3 % of the peaks ([Fig. 8c,d](#F8){ref-type="fig"}). Overall, 908 peaks (32% of the total) contained both TCF-LEF and Runx motifs ([Fig. 8e](#F8){ref-type="fig"}). Motif analysis of the 6,577 weak TCF-1 binding peaks revealed a similar trend, with TCF-LEF and Runx motifs found in 37.3% and 41.4 % of the peaks, respectively, and 1,257 peaks containing both motifs ([Supplementary Fig. 8d,e,f](#SD1){ref-type="supplementary-material"}). By applying our stringent peak calling setting to the Runx3 ChIP-seq data in CD8^+^ T cells^[@R36]^, we identified 4,785 Runx3 binding peaks, and 1,270 of these overlapped with strong TCF-1 binding peaks. These high-throughput data suggest that TCF-LEF and Runx factors may have a broadly cooperative role in gene regulation. It has been shown that Runx3 interacts with TCF-4 and attenuated TCF-4-β-catenin signaling during intestinal tumorigenesis^[@R37]^. To further substantiate this point, we overexpressed Myc-tagged Runx3 with Flag-tagged full-length p45 TCF-1 isoform in 293T cells and immunoprecipitated the cell lysates with anti-Flag or control IgG. Immunoblotting with anti-Myc revealed that TCF-1 was co-immunoprecipitated with Runx3 ([Fig. 8f](#F8){ref-type="fig"}). In the reciprocal experiment, immunoprecipitation with anti-Myc detected Flag-tagged p45 TCF-1 ([Fig. 8g](#F8){ref-type="fig"}). The p33 isoform of TCF-1, which is truncated on the N-terminus and lacks the β-catenin-binding domain, was also coimmunoprecipitated with Runx3 ([Fig. 8g](#F8){ref-type="fig"}). Runx3 recruits the Groucho-TLE corepressors through its last five amino acids, the "VWPRY" motif, in the C-terminus^[@R38]^. Specific deletion of this sequence in mouse germline causes CD4 derepression in CD8^+^ T cells^[@R38]^, similar to the complete deletion of Runx3, indicating an essential role for Runx3-mediated recruitment of Groucho-TLE corepressors in *Cd4* silencing. Because TCF-LEF factors interact with Groucho-TLE^[@R14]^, the interaction between Runx3 and TCF-1 may be bridged by these corepressor proteins. To determine if Runx3 can directly interact with TCF-1, we generated a C-terminus-truncated version of Runx3d (Runx3dΔC) that specifically lacked the VWRPY motif. The Runx3dΔC mutant did coimmunoprecipitate with TCF-1 ([Fig. 8h](#F8){ref-type="fig"}), suggesting that direct physical interaction between TCF-1 and Runx3 can occur independent of the Groucho-TLE corepressors.

To further delineate the TCF-Runx cooperation *in vivo*, we examined CD4 derepression in CD8^+^ T cells. In *Tcf7*^−/−^ or *Runx3*^−/−^ mice, a small portion of mature CD8^+^ thymocytes showed CD4 derepression; however, in *Tcf7*^−/−^*Runx3*^−/−^ mice, a much larger portion of CD8^+^ T cells expressed CD4 ([Fig. 8i, j](#F8){ref-type="fig"}). *Tcf7*^−/−^*Lef1*^−/−^ mice showed stronger CD4 derepression in CD8^+^ T cells than *Tcf7*^−/−^ mice, because of the functional redundancy between TCF-1 and LEF-1 ([Fig. 2](#F2){ref-type="fig"} and [Fig. **8i**](#F8){ref-type="fig"}), while *Tcf7*^−/−^*Lef1*^−/−^*Runx3*^−/−^ mice showed a further increase in the frequency of CD8\*4 cells within the mature TCRβ^hi^ CD8^+^ thymocytes, with cells in the CD8^+^CD4^−^ gate showing a strong shift toward increased CD4 expression ([Fig. 8i, j](#F8){ref-type="fig"}), analogous to what is observed in Runx3^−/−^Runx1^+/-^ or Runx3^−/−^ Runx1^+/Δ~446~^ mice^[@R10],\ [@R39]^. These observations demonstrate a functional synergy between TCF-LEF and Runx factors in achieving stable *Cd4* silencing in CD8^+^ T cells.

Discussion {#S9}
==========

TCF-1 and LEF-1 have well documented roles in early T cell development. By conditional targeting of both factors, our studies reveal their roles in late developmental stages, CD4^+^ *vs*. CD8^+^ lineage choice and establishing CD8^+^ T cell identity. Lineage specification and commitment involve activation of lineage-appropriate genes and inactivation of lineage-inappropriate genes^[@R40]^. Before lineage commitment, the DP precursors are likely biased toward CD4^+^ specification^[@R5]^, because the post-select DP thymocytes lacking both Th-POK and Runx complex adopt a CD4^+^ T cell fate^[@R11]^. In addition to Myb, Tox and GATA-3, we identified TCF-1 and LEF-1 as independent factors in promoting CD4^+^ lineage specification. Whereas Myb is downregulated, Tox and GATA-3 are upregulated by positive selection signals. In contrast, TCF-1 and LEF-1 expression is induced in early DN stages, with TCF-1 abundantly expressed thereafter and LEF-1 exhibiting further induction in post-select DP thymocytes. Thus, TCF-1 and LEF-1 may act as a constant "inner drive" toward the CD4^+^ T cell lineage.

TCF-1 contributes to CD4^+^ T cell lineage commitment by direct positive regulation of *Thpok. Thpok* expression was diminished but not completely abrogated by TCF-1 deficiency. Hypomorphic Th-POK expression is known to cause redirection of CD4^+^ to CD8^+^ T cell lineage^[@R11]^, indicating that a threshold of Th-POK expression is required for complete commitment to the CD4^+^ lineage to occur. The diminished expression of *Thpok* in TCF-1-deficient post-select DP and CD4^+^8^lo^ thymocytes was sufficient to reduce CD4^+^ T cell output and cause CD8^+^ lineage redirection when tested on a β2m^−/−^ background or with an MHC-II-restricted TCR. Although significant CD4 derepression in *Tcf7*^−/−^*Lef1*^−/−^ CD8^+^ T cells precluded us from decisive gene expression analysis in post-select DP cells lacking both TCF-1 and LEF-1, we did observe stronger CD4^+^ to CD8^+^ lineage redirection in all models tested, suggesting that loss of TCF-1 and LEF-1 causes a more severe reduction in *Thpok* expression.

TCF-1 deficiency also caused increased expression of *Runx3d* in the bipotent post-select DP and CD4^+^8^lo^ thymocytes. However, this increase is most likely secondary to decreased *Thpok* expression, because a Th-POK transgene suppressed *Runx3d* expression in both wild-type and *Tcf7*^−/−^ cells. In addition, whereas ectopic Th-POK expression restored CD4^+^ T cell output in *Tcf7*^−/−^ mice, Runx3 deletion failed to do so. On the other hand, in mature TCRβ^hi^ thymocytes from *Tcf7*^−/−^*Lef1*^−/−^ mice, the Th-POK transgene was able to suppress CD8^+^ T cell differentiation and lineage redirection in β2m^−/−^ chimeric hosts, but was inefficient in restoring CD4^+^ T cell numbers. This resembles impaired generation of CD4^+^ SP thymocytes caused by CD4-Cre-mediated inactivation of GATA-3, which cannot be rectified by the Th-POK transgene^[@R6]^. Therefore, loss of both TCF-1 and LEF-1 may have perturbed expression of other critical genes that promote CD4^+^ T cell differentiation, in addition to Th-POK.

In spite of the intrinsic bias toward CD4^+^ lineage specification, the Th-POK expression and/or activity is opposed by Runx3d to ensure the MHC-I signal-selected DP thymocytes to commit to the CD8^+^ T cell lineage. It is well accepted that potent and persistent TCR signaling promotes CD4^+^ lineage choice. Recent studies further demonstrate that intrathymic cytokine signaling, rather than TCR, promotes CD8^+^ lineage choice^[@R41],\ [@R42]^. Indeed, IL-7 is shown to induce the expression of Runx3d, which in turn activates the *Thpok* silencer^[@R41]^. It is important to note that IL-7-derived signals inhibit the expression of TCF-1 and LEF-1^[@R43]^. Given our new findings that TCF-1 and LEF-1 positively regulate Th-POK, IL-7 signaling may annihilate Th-POK expression *via* multiple mechanisms, including repressing its positive regulators (such as TCF-1 and LEF-1) in addition to inducing its negative regulator, Runx3d.

Once a lineage decision is made, lineage-inappropriate genes must be silenced to ensure that the cell identity is inheritably maintained. Runx factors play an important role in *Cd4* gene silencing in CD8^+^ lineage-committed cells^[@R4],\ [@R44]^. Our results reveal a critical contribution of TCF-1 and LEF-1 to *Cd4* silencing. TCF-1 and Runx3 physically interacted with each other and exhibited strong cooperativity in silencing the *Cd4* gene in CD8^+^ T cells. Although it remains to be elucidated if TCF-1 is recruited to the *Cd4* silencer directly by the DNA element(s) or indirectly by Runx factors, Runx and TCF-LEF factors are both essential components of a protein complex that occupies the *Cd4* silencer. Compelling evidence indicates that epigenetic mechanisms are involved in inheritable *Cd4* silencing in CD8^+^ T cells^[@R45]^. Identification of TCF-LEF factors in CD4 repression thus expands the contact surface of the *Cd4* silencing complex for recruiting histone modification enzymes. Beyond *Cd4* gene silencing, the cooperativity between TCF-LEF and Runx factors might be essential for positive regulatory functions in other gene regulatory contexts, or extend to different cell types such as hematopoietic stem cells, as previously suggested^[@R46]^.

While TCF-1 and LEF-1 are required for *Cd4* silencing in CD8^+^ T cells, early deletion of these factors did not cause aberrant expression of CD4 in DN thymocytes^[@R18]^. In contrast, loss of Ikaros results in the opposite effect, causing CD4 derepression in DN thymocytes but not in CD8^+^ T cells^[@R47]^. Among Runx factors, Runx1 has a more dominant role in CD4 repression in DN cells, but Runx3 is more potent for *Cd4* silencing in CD8^+^ T cells. Thus, the protein complex at the *Cd4* silencer appears to undergo dynamic component changes as thymocytes progress through different developmental stages. TCF-1 and LEF-1 are both expressed in multiple isoforms, with the full-length isoform having the capacity to interact with β-catenin. The short isoforms are found to have suppressive and/or dominant negative functions^[@R16],\ [@R21]^, and in fact, p33 TCF-1 interacts with Runx3. It would be interesting to determine if there is a division of labor between the full-length and short isoforms of TCF-1 and LEF-1 in *Cd4* silencing in CD8^+^ T cells, and by extension, in promoting *Thpok* expression in lineage choice.

Although ablation of the Runx complex causes derepression of both *Cd4* and *Thpok* in CD8^+^ T cells^[@R10]^, loss of TCF-1 and LEF-1 specifically derepressed *Cd4,* but not *Thpok*. Consistent with this observation, ChIP-seq of TCF-1 in CD8^+^ T cells revealed no direct association of TCF-1 with the *Thpok* locus, and the previously defined *Thpok* silencer (DRE) does not contain a TCF-LEF consensus motif. Thus, the TCF-LEF and Runx cooperativity is highly gene context-dependent. In addition, regulation of *Thpok* by TCF-1 at the GTE was restricted to the bipotent precursors, implying that the GTE may not be accessible to TCF-1 in CD8^+^ lineage-committed T cells.

In summary, our studies demonstrate a role switch for TCF-1 and LEF-1 in late stages of T cells development. They promote CD4^+^ T cell fate decision in DP and CD4^+^8^lo^ thymocytes by positively regulating Th-POK without directly involving Runx3, In CD8^+^ lineage-committed T cells; however, TCF-1 and LEF-1 cooperate with Runx3 to repress the lineage-inappropriate *Cd4* gene. These new findings reveal that the same transcriptional regulator contributes to fate decision and establishment of cell identity through distinct genetic and molecular wiring.

ONLINE METHODS {#S10}
==============

Animals {#S11}
-------

The *Tcf7*-targeted mice were obtained from Institut Clinique de la Souris, France, part of the IKMC. Following rederivation at the animal use facility, University of Iowa, the mice were crossed with Rosa26-Flippase knock-in mice (Jackson Laboratory) to delete the LacZ-Neo cassette flanked by the Frt sites ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), converting the targeted allele into *Tcf7*-floxed allele (*Tcf7*^fl/+^). The *Lef1*^fl/fl^ mice were previously described^[@R18]^, Runx3^fl/fl^ mice were from the Jackson Laboratory, β2m^−/−^ and *H2-Ab1*^−/−^ mice from Taconic, Th-POK TG mice were provided by R. Bosselut^[@R29]^. All animals were analyzed at 5-10 weeks of age, and both genders included without randomization or "blinding". All the BM chimeras were analyzed within 6-10 weeks after the BM transplantation. For all mouse phenotypic analysis, at least 5 animals of each genotype were analyzed in at least 3 independent experiments. All mouse experiments were performed under protocols approved by the Institutional Animal Use and Care Committee of the University of Iowa.

Flow cytometry {#S12}
--------------

Single cell suspension was prepared from thymus and spleen and surface-stained as previously described^[@R18]^. All fluorochrome-conjugated antibodies were from eBiosciences or BD Biosciences. The antibodies and their clone numbers are CD4 (RM4-5), CD8α (53-6.7), CD8β (H35-17.2); TCRβ (H57-597), CD24 (M1/69), CD69 (H1.2F3), CD45.2 (104), B220 (RA3-6B2), Gr-1 (RB6-C5), NK1.1 (PK136), TER-119 (TER-119), γδTCR (GL3), Vα2 TCR (B20.1), IFN-γ (XMG1.2), IL-2 (JES6-5H4), and Streptavidin (eBiosciences Cat. No. 48-4317-82). Granzyme B (GB11) and control mouse IgG1 (Cat. No. MG104) were from Life Technologies. Data were collected on FACSVerse (BD Biosciences) and analyzed with FlowJo software (Version X, TreeStar).

Generation of BM chimeras {#S13}
-------------------------

β2m^−/−^ mice were crossed with the B6.SJL strain to acquire homozygous expression of CD45.1 and used as recipients. Whole BM cells were isolated from various donors, and 2 × 10^6^ cells were transplanted into irradiated recipients *via* tail vein injection.

Luciferase assays {#S14}
-----------------

The 473-bp WT GTE was PCR-amplified, and mutant GTE was synthesized (GenScript) with proper flanking enzyme sites. These segments were cloned into the pGL3 promoter vector (Promega), *via* the KpnI and NheI sites upstream of the SV40 promoter or *via* the BamHI and SalI sites downstream of the luciferase gene. The reporter constructs were transfected into EL-4 cells by electroporation (GenePulser Xcell, BioRad) or 293T cells using Lipofectamine 2000 (Life Technologies) following standard protocols^[@R48]^. pRL-TK, which expresses Renilla luciferase driven by a thymidine kinase promoter, was cotransfected as an internal control. Forty-eight hrs later, cell lysates were extracted and analyzed for luciferase activity with the Dual-Luciferase Reporter Assay System (Promega).

Gene expression assay {#S15}
---------------------

Target cell populations were sorted from thymocytes or splenocytes, RNA extraction, reverse-transcription, and quantitative PCR were performed as described^[@R18]^. The primer sequences are in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Chromatin immunoprecipitation (ChIP) {#S16}
------------------------------------

Post-select DP and CD4^+^8^lo^ thymocytes, mature CD8^+^ or CD4^+^ SP thymocytes, or splenic CD8^+^ T cells were sorted from either wild-type C57BL/6 or *Tcf7*^−/−^ mice. The cells were cross-linked with 1% formaldehyde in medium for 5 minutes, processed using truChIP Chromatin Shearing Reagent Kit (Covaris), and sonicated for 5 minutes on Covaris S2 ultrasonicator. The sheared chromatin was immunoprecipitated with anti-TCF-1^[@R30]^ or control IgG and washed as previously described. The immunoprecipitated DNA segments were used for library construction or PCR quantification. For calculation of enriched TCF-1 binding in a given cell type in ChIP-PCR experiments, each TCF-1 ChIP sample was first normalized to corresponding IgG ChIP sample, and the signal at a target region was then normalized to that at the *Hprt1* or *Gapdh* promoter region. The primers for assessing enriched TCF-1 binding are listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

ChIP-seq and data analysis {#S17}
--------------------------

DNA segments from ChIP were end-repaired and ligated to indexed Illumina adaptors followed by low-cycle PCR. The resulting libraries were sequenced with the Illumina Hiseq-2000 platform. Sequencing reads were mapped to the mouse genome (mm9) using Bowtie v.0.12.5. The mapping statistics are summarized in the following table: SampleTotal numbers\
of readsNumbers of\
mapped readsTcf1 ChIP24,390,26823,262,097 (95.4%)IgG ChIP48,752,15446,601,382 (95.6%)

MACS^[@R34]^ was used for peak calling with two sets of cutoffs. The first set used ≥ 4 fold enrichment, p-value \< 10^−5^, and FDR \< 5% and thus identified strong TCF-1 binding peaks. The second set used the same fold enrichment and FDR cutoffs but p \< 10^−3^, which identified additional weak TCF-1 binding peaks. The identified TCF-1 peaks were analyzed with MEME-ChIP v.4.9.0 to define consensus DNA binding motifs^[@R49]^. Peak sequences were padded with 200 bp genomic sequences on both sides for motif scanning. Patser v.3b was used to scan each TCF-1 peak region for the co-occurrence of TCF-1 and Runx binding sites^[@R50]^.

Immunoprecipitation and immunoblotting {#S18}
--------------------------------------

The *Tcf7* and *Runx3d* coding sequence was amplified from CD8^+^ T cell cDNA and cloned in Mig-R1 retroviral vector, and a 3×Flag tag was placed in-frame on the N-terminus of TCF-1. The expression plasmids were transfected into 293T cells using Lipofectamine 2000 (Life Technologies), and 48 hours later, cell lysates were extracted and incubated overnight with 2 μg of anti-Runx3 (R&D Systems, clone 527327), anti-Flag (Sigma-Aldrich, clone M2), or mouse IgG, followed by 2-hr incubation with Dynabeads Protein G (Life Technologies). After proper washing, the immunoprecipitated samples were analyzed by immunoblotting with anti-Myc (Cell Signaling Technologies, clone 71D10), Flag or Runx3 antibodies.

For assessing TCF-1 and LEF-1 deletion efficiency, pre- and post-select DP thymocytes (5 ×10^5^ each) were sorted, and the lysates were probed with TCF-1 or LEF-1 antibodies (Cell Signaling Technology, clone C46C7 and C18A7, respectively), or anti-β-actin (Santa Cruz Biotechnology, clone I-19) as an equal loading control.

Statistical analysis {#S19}
--------------------

Data sets were analyzed with the Student's *t*-test with a two-tailed distribution assuming equal sample variance.
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![CD4-Cre-mediated deletion of TCF-1 or both TCF-1 and LEF-1 impairs CD4^+^ SP thymocyte development\
(**a**) Complete ablation of TCF-1 and LEF-1 proteins in post-select DP thymocytes. Thymocytes were surface-stained, FACS-sorted for TCRβ^lo-med^CD69^−^CD4^+^CD8^+^ as pre-select DP (PreDP), and TCRβ^hi^CD24^+^CD69^+^CD4^+^CD8^+^ as post-select DP (PostDP) thymocytes. Note that both TCF-1 and LEF-1 are expressed in multiple isoforms in thymocytes due to differential promoter usage and alternative splicing. Data are representative from 2 experiments. (**b**) Total thymic cellularity. Data are means ± s.d. from ≥ 5 independent experiments. \*, p \< 0.05; \*\*, p \< 0.01. (**c**) and (**d**) Analysis of post-select thymocytes. The TCRβ^hi^ thymocytes (**c**) are further fractionated into immature (CD24^+^CD69^+^) and mature (CD24^−^ CD69^−^) subsets (**d**). The frequency of each subset is shown. (**e**) Loss of TCF-1 or both TCF-1 and LEF-1 diminishes the frequency of CD4^+^ SP thymocytes. The immature CD69^+^CD24^+^TCRβ^hi^ thymocytes were fractionated into DP, CD4^+^CD8^lo^, CD4^+^ SP and CD8^+^ SP subsets with their frequencies shown. (**f**) Loss of TCF-1 or both TCF-1 and LEF-1 causes derepression of the CD4 coreceptor in CD8^+^ lineage thymocytes. The mature CD69^−^CD24^−^TCRβ^hi^ thymocytes were separated into CD4^+^ and CD8^+^ subsets. The values are frequencies of CD4^+^ and CD8^+^ cells, with the latter including both CD8^+^CD4^−^ and CD8^+^CD4^+^ cells that appear in *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ mice. Data in **c-f** are representative of ≥ 5 independent experiments.](nihms-589173-f0001){#F1}

![The CD4^+^CD8^+^ (CD8\*4) mature thymocytes in *Tcf7*^−/−^*Lef1*^−/−^ mice belong to the CD8^+^ lineage\
(**a**) The *Tcf7*^−/−^*Lef1*^−/−^ CD8\*4 mature thymocytes express CD8β. Mature TCRβ^hi^ thymocytes were analyzed for CD4, CD8α, and CD8β expression. (**b**) The *Tcf7*^−/−^*Lef1*^−/−^ CD8\*4 mature thymocytes express CD8^+^-characteristic genes. Shown is relative expression of each gene after normalization to *Hprt1*. Mature CD4^+^, CD8^+^, and CD8\*4 thymocytes were sorted from *Tcf7*^−/−^*Lef1*^−/−^ mice and littermate controls and analyzed for gene expression (n ≥ 3). (**c**) The *Tcf7*^−/−^*Lef1*^−/−^ CD8\*4 subset persists in the absence of MHC-II I-A and I-E molecules. *Tcf7*^−/−^*Lef1*^−/−^ and control mice were crossed to an *H2-Ab1*^−/−^ background, and the mature TCRβ^hi^ thymocytes were analyzed for CD4^+^ and CD8^+^ lineage distribution. Shown are representative data from 3 experiments.](nihms-589173-f0002){#F2}

![Deficiency in TCF-1 or both TCF-1 and LEF-1 redirects CD4^+^ T cells to the CD8^+^ lineage\
(**a**) Loss of TCF-1 or both TCF-1 and LEF-1 greatly diminishes CD4^+^ T cell output. Numbers of mature CD4^+^ and CD8^+^ SP thymocytes are shown as means ± s.d. (n ≥ 6). (**b**) Loss of TCF-1 or both factors reverses the CD4/CD8 ratio. Ratio of mature CD4^+^ to CD8^+^ cells was calculated from **a**. The horizontal line denotes mean value. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001. (**c**) MHC-II-selected thymocytes are redirected to CD8^+^ lineage in the absence of TCF-1 or both factors. BM cells from *Tcf7*^−/−^, *Tcf7*^−/−^*Lef1*^−/−^, or littermate controls were transplanted into lethally irradiated CD45.1^+^ congenic β2m^−/−^ mice. Six weeks later, donor-derived (CD45.2^+^) mature CD69^−^CD24^−^ TCRβ^hi^ thymocytes were analyzed for CD4^+^ and CD8^+^ lineage distribution. Representative contour plots (**c**) are from 4 independent experiments. Numbers of mature CD4^+^ and CD8^+^ thymocytes in the BM chimeras are shown in (**d**) as means ± s.d. (n ≥ 14). \*\*\*, p\<0.001. (**e**) and (**f**) OT-II TCR transgenic T cells adopt a CD8^+^ fate in the absence of TCF-1 or both factors. The OT-II TG was crossed onto *Tcf7*^−/−^, *Tcf7*^−/−^*Lef1*^−/−^, or littermate controls. After gating on the Vα2^+^TCRβ^hi^ subset, mature CD24^−^ thymocytes were analyzed for CD4^+^ and CD8^+^ lineage distribution. Representative contour plots (**e**) are shown (n ≥ 5 from 5 experiments). Frequencies of mature CD4^+^ and CD8^+^ OT-II thymocytes are summarized in (**f**). \*\*\*, p\<0.001.](nihms-589173-f0003){#F3}

![TCF-1 deficiency decreases *Thpok* but increases *Runx3d* expression in the bipotent precursors\
Thymocytes from *Tcf7*^−/−^ and littermate controls were sorted for 3 subsets, pre-select DP (PreDP), post-select DP (PostDP), and CD4^+^8^lo^ intermediate (IM). The expression of indicated genes was measured by quantitative RT-PCR. To demonstrate kinetic changes of each gene during these developmental stages, the expression of each gene in control post-select DP (after normalization to *Hprt1*) was arbitrarily set to 1, and the relative expression of this gene in all other control or *Tcf7*^−/−^ subsets was then normalized accordingly and presented as fold changes. Data are means ± s.d. from 4 independent experiments (n ≥ 6). ND, not reliably detected. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001.](nihms-589173-f0004){#F4}

![Ectopic expression of Th-POK rectifies defects in CD4^+^ T cell differentiation caused by loss of TCF-1\
(**a**) Th-POK TG represses CD8^+^ differentiation in the absence of TCF-1 or both TCF-1 and LEF-1. Th-POK TG was crossed onto *Tcf7*^−/−^ or *Tcf7*^−/−^*Lef1*^−/−^ mice. The immature and mature TCRβ^hi^ thymocytes were analyzed for CD4^+^ and CD8^+^ lineage distribution. Frequency of each subset is shown in the representative data from ≥ 3 experiments. (**b**) Cumulative data on the impact of Th-POK TG on the numbers of total, mature CD4^+^ and CD8^+^ SP thymocytes. Data are means ± s.d. from 5 experiments (n ≥ 6). \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; NS, not statistically significant. (**c**) Th-POK TG prevents CD4^+^ to CD8^+^ lineage redirection caused by deficiency in TCF-1 or both TCF-1 and LEF-1. BM cells from Th-POK TG, Th-POK TG *Tcf7*^−/−^, or Th-POK TG *Tcf7*^−/−^*Lef1*^−/−^ were transplanted into irradiated CD45.1^+^ β2m^−/−^ recipients. Six weeks later, CD45.2^+^ mature TCRβ^hi^ thymocytes were analyzed for CD4^+^ and CD8^+^ distribution. Representative data from ≥ 3 experiments are shown. (**d**) Ectopic expression of Th-POK represses *Runx3d* in the presence or absence of TCF-1. Post-select DP (PostDP) and CD4^+^8^lo^ intermediate (IM) thymocytes were sorted and analyzed for gene expression. Shown is relative expression of each gene after normalization to *Hprt1*. Data are representative from 3 independent experiments. \*\*\*, p\<0.001.](nihms-589173-f0005){#F5}

![TCF-1 acts through the GTE in the *Thpok* gene locus\
(**a**) Identification of conserved TCF-LEF motifs in the *Thpok* gene locus, as marked by arrows (A through G). Partial structure of the *Thpok* gene is shown, with filled bars denoting exons. Open bars denote the following *cis*-elements, DRE (distal regulatory element, also known as *Thpok* silencer), GTE, and PRE (proximal regulatory element). The sizes of exons and regulatory elements are not drawn to scale. (**b**) TCF-1 binds to the GTE in the *Thpok* locus. Post-select DP and CD4^+^8^lo^ thymocytes were sorted together from WT or *Tcf7*^−/−^ mice and used in ChIP with anti-TCF-1 or control IgG followed by quantitative PCR. Enrichment by TCF-1 antibody at each motif or locus was first normalized to IgG, and then normalized to that at the *Gapdh* locus. Two known TCF-1 target genes, *Lef1* and *Axin2*, were detected as positive controls. Data are pooled results from ≥3 experiments. \*\*, p\<0.01. (**c**) Mutation of TCF-1 sites in the GTE abrogates its enhancer activity. The luciferase reporter constructs (shown on the left) were transfected into the EL-4 cells by electroporation, and 48 hrs later the luciferase activity was measured. Luciferase activity driven by the SV40 alone (pGL3 promoter) is arbitrarily set to 1, and that containing WT or mutant (Mut) GTE was normalized accordingly. Data are means ± s.d. from 2 experiments (n = 3). \*, p\<0.05; \*\*, p\<0.01.](nihms-589173-f0006){#F6}

![Deletion of Runx3 does not rescue CD4^+^ differentiation defects caused by loss of TCF-1 and LEF-1\
(**a**) CD4-Cre*-Runx3*^fl/fl^ (*Runx3*^−/−^) mice were crossed with *Tcf7*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^ strains to acquire *Tcf7*^−/−^*Runx3*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^*Runx3*^−/−^ animals. The immature and mature TCRβ^hi^ thymocytes were analyzed for CD4^+^ and CD8^+^ lineage distribution. Frequency of each subset is shown in the representative data from 4 experiments. (**b**) Cumulative data on the impact of Runx3 deletion on numbers of mature CD4^+^ and CD8^+^ SP thymocytes (n ≥ 5 from 4 experiments). (**c**) Deletion of Runx3 does not reverse the decrease in *Thpok* expression caused by TCF-1 deficiency. Post-select DP (PostDP) and CD4^+^8^lo^ intermediate (IM) thymocytes were sorted and analyzed for *Thpok* gene expression. Shown is relative *Thpok* expression after normalization to *Hprt1*. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001. NS, not statistically significant. (**d**) Deletion of Runx3 does not prevent CD4^+^ to CD8^+^ lineage redirection caused by deficiency in TCF-1 or both TCF-1 and LEF-1. BM cells from *Runx3*^−/−^, *Tcf7*^−/−^*Runx3*^−/−^ and *Tcf7*^−/−^*Lef1*^−/−^*Runx3*^−/−^ mice were transplanted into irradiated CD45.1^+^ β2m^−/−^ recipients. Six weeks later, CD45.2^+^ mature TCRβ^hi^ thymocytes were analyzed for CD4^+^ and CD8^+^ distribution. Data are representative from 3 experiments (n ≥ 6).](nihms-589173-f0007){#F7}

![TCF-LEF and Runx factors cooperate in *Cd4* silencing in CD8^+^ lineage T cells\
(**a**) Genome-wide mapping of TCF-1 occupancy reveals its direct association with the *Cd4* silencer. Splenic CD8^+^ T cells were used in ChIP followed by high throughput sequencing, and ChIP-Seq track wiggle files were uploaded to the UCSC genome browser for visualization of enriched TCF-1 binding peaks. Top two tracks are sequencing reads from ChIP with anti-TCF-1 and IgG, respectively. The bottom track shows fold enrichment of TCF-1 binding peaks. All tracks are shown for the *Axin2* and *Cd4* gene loci, with their transcription orientations marked with arrows. (**b**) Binding of TCF-1 to the *Cd4* silencer is specific to CD8^+^ T cells. CD8^+^ or CD4^+^ SP thymocytes were sorted from WT or *Tcf7*^−/−^ mice and used in ChIP with anti-TCF-1 or control IgG. Enrichment at the *Gapdh* and *Lef1* loci was measured as negative and positive controls, respectively. Data are pooled results from at least 3 independent experiments. \*, p\<0.05; \*\*, p\<0.01. (**c**) TCF-LEF motif and (**d**) Runx motif enriched in the TCF-1 ChIP-seq peaks. (**e**) Distribution of TCF-LEF and Runx motifs in the TCF-1 binding peaks is summarized in a Venn diagram. (**f**) Runx3 is coimmunoprecipitated with TCF-1. Myc-tagged Runx3 and Flag-tagged full-length TCF-1 were overexpressed in 293T cells, and the lysates were immunoprecipitated with anti-Flag or control IgG followed by immunoblotting with anti-Myc. Lysate input without immunoprecipitation was blotted to detect the expressed proteins. (**g**) Both p45 and p33 TCF-1 isoforms are coimmunoprecipitated with Runx3. Myc-tagged Runx3 was overexpressed together with Flag-tagged full length (p45) or p33 TCF-1 isoform. The lysates were immunoprecipitated with anti-Myc and then immunoblotted with anti-Flag. As negative controls, pCMV-Myc was transfected in place of Myc-Runx3. (**h**) TCF-1 is coimmunoprecipitated with full length Runx3d or Runx3d lacking the VWRPY motif (Runx3ΔC). Runx3d or Runx3ΔC were overexpressed together with Flag-tagged full length TCF-1 in 293T cells. The cell lysates were immunoprecipitated with anti-Runx and then blotted with anti-Flag. Data in (**f**)-(**h**) are representative of at least 3 independent experiments. (**i**) and (**j**) TCF-1 and LEF-1 cooperate with Runx3 in *Cd4* gene silencing. Mature TCRβ^hi^ thymocytes were analyzed in the compound knockout mice. Representative contour plots are shown in (**i**), and the values are percentages of CD8^+^CD4^−^ and CD8\*4 subsets within the CD8^+^ population (to avoid the influence of varied CD4^+^ frequency). Cumulative data on the frequency of the CD8\*4 subset are in (**j**). n ≥ 5. \*\*\*, p \< 0.001.](nihms-589173-f0008){#F8}

[^1]: Current address: Dept. of Nephrology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P. R. China 200092
